Viridian Therapeutics Inc (VRDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.51B
Last updated: Nov 17, 2026 at 4:14 PM ET
Viridian Therapeutics Inc (VRDN) Statistics
Viridian Therapeutics (VRDN) has a market cap of $3.51B and an enterprise value of $3.58B. It kept -1724.06% of revenue as net income over the last 12 months. Its share count is up 38.67% from a year earlier.
Total Valuation
Enterprise value is 2.01% above the market cap, as debt exceeds cash.
| Market Cap | $3.51B |
|---|---|
| Enterprise Value | $3.58B |
| Latest price (Nov 17, 2026) | $30.06 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 129.6x and 5.9x. Its year-end P/S ranged from 2.0x to 526.4x from 2016 to 2025.
| P/S Ratio | 129.6x |
|---|---|
| Forward P/S | 46.9x |
| P/B Ratio | 5.9x |
| P/TBV Ratio | 6.0x |
Price Statistics
The stock is up 4.48% over 52 weeks and trades 30.58% above its 50-day average.
| Beta (1Y) | 1.11 |
|---|---|
| 52-Week Change | +4.48% |
| 1-Month Change | +44.52% |
| 3-Month Change | +21.21% |
| 6-Month Change | +88.23% |
| 5-Year Change | +36.30% |
| 10-Year Change | -69.46% |
| Total Return (1Y) | +4.48% |
| Total Return (3Y CAGR) | +23.70% |
| Total Return (5Y CAGR) | +8.88% |
| Return vs SPY (1Y) | -6.42% |
| Max Drawdown (1Y) | -60.63% |
| Max Drawdown (3Y) | -60.63% |
| Sharpe Ratio (1Y) | 0.07 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $23.02 |
| 200-Day Average | $21.52 |
| 52-Week Range | $13.18 to $34.29 |
| RSI (14 Days) | 70.1 |
| Average Volume (20 Days) | 2.85M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 14.46x current liabilities, and total debt is 0.42x shareholder equity.
| Current Ratio | 14.46x |
|---|---|
| Quick Ratio | 14.46x |
| Debt / Equity | 0.42x |
| Interest Coverage | -15.75x |
Returns and Efficiency
Return on invested capital is -41.75% over the last 12 months, against a 5-year average of -36.78%.
| Return on Equity (ROE) | -78.11% |
|---|---|
| Return on Assets (ROA) | -44.09% |
| Return on Invested Capital (ROIC) | -41.75% |
| Return on Capital Employed (ROCE) | -45.43% |
| ROE (5Y Average) | -43.32% |
| ROA (5Y Average) | -38.35% |
| ROIC (5Y Average) | -36.78% |
| Asset Turnover | 0.03x |
| Inventory Turnover | 49.06x |
| Receivables Turnover | 0.50x |
| Cash Conversion Cycle | -837 days |
Scores
VRDN has an Altman Z-Score of 2.02, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.02 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $26.31M over the last 12 months is down 62.83% from the 12 months before.
| Revenue | $26.31M |
|---|---|
| Revenue Growth (YoY) | -62.83% |
| Gross Profit | $24.46M |
| Operating Income | -$468.66M |
| Pretax Income | -$453.58M |
| Net Income | -$453.58M |
| EBITDA | -$434.77M |
| EBIT | -$435.47M |
| Reported EPS (TTM) | -$3.84 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 56.38% of the $1.03B in total assets.
| Cash and Equivalents | $172.86M |
|---|---|
| Total Debt | $243.27M |
| Net Debt | $70.41M |
| Net Debt Per Share | $0.62 |
| Working Capital | $943.08M |
| Shareholder Equity | $580.70M |
| Book Value Per Share | $5.12 |
| Tangible Book Value | $570.91M |
| Tangible Book Per Share | $5.03 |
| Total Assets | $1.03B |
| Total Liabilities | $447.97M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.94M of capital spending, operating cash flow left -$343.44M of free cash flow.
| Operating Cash Flow | -$341.50M |
|---|---|
| Capital Expenditures | $1.94M |
| Free Cash Flow | -$343.44M |
| FCF Per Share | -$3.02 |
| Depreciation and Amortization | $701.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1781.38%.
| Gross Margin | 92.98% |
|---|---|
| Operating Margin | -1781.38% |
| Pretax Margin | -1724.06% |
| Net Margin | -1724.06% |
| EBITDA Margin | -1652.55% |
| EBIT Margin | -1655.22% |
| FCF Margin | -1305.42% |
Growth
Revenue grew 241.95% a year over 3 years.
| Revenue Growth (3Y CAGR) | +241.95% |
|---|---|
| Revenue Growth (5Y CAGR) | +132.18% |
| Book Value Per Share Growth (2Y CAGR) | -2.17% |
| Tangible Book Per Share Growth (2Y CAGR) | -2.17% |
Dividends and Yields
VRDN does not pay a dividend. Its free cash flow yield is -10.07%.
| FCF Yield | -10.07% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-15 reverse split on Nov 13, 2020.
| Last Split Date | Nov 13, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 8 similar companies, VRDN has the 3rd highest P/S.
P/S RatioPeer median 9.1x
ROICPeer median -29.73%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +49.38%
| P/S Ratio | 129.6x vs 9.1x median |
|---|---|
| ROIC | -41.75% vs -29.73% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -62.83% vs +49.38% median |
Analyst Forecast
Consensus estimates put revenue growth at 110.08% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +110.08% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VRDN
What is VRDN's market cap?
Viridian Therapeutics has a market cap of $3.51B. Its enterprise value, which adds debt and subtracts cash, is $3.58B.
How many shares of VRDN are outstanding?
Viridian Therapeutics has 113.41M shares outstanding. The count is up 38.67% from a year earlier.
Does VRDN pay a dividend?
No. Viridian Therapeutics does not pay a dividend.
How much debt does VRDN have?
Viridian Therapeutics has $243.27M of total debt and $172.86M of cash and equivalents, a net debt position of $70.41M.
VRDN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors